Editorials

CHEST. 2003;123(3) 

In This Article

Heliox Redux

Helium is an inert, colorless gas. It was discovered by spectroscopic methods during an eclipse of the sun in India in 1868 and, thus, was named from the Greek word helios, which means sun. It was not isolated until 1895 by Sir William Ramsey, and by Nils Langlet and P.T. Cleve. Its first major uses in the first third of the 20th century were for filling airships and balloons during World War I and for divers in a mixture with oxygen. Alvan Barach[1] first used it for medical purposes in 1934 and confirmed the biological inertness of helium by exposing mice to 79% helium and 21% oxygen for 2 months without deleterious effects.[2] He reported the successful usage of helium-oxygen mixtures in four cases of asthma in adults and two cases of upper airway obstruction in infants.[3] Of interest, the patients were relieved of their dyspnea in 6 to 10 breaths, and when the helium was removed the dyspnea came back in 3 or 4 breaths. After the explosion of the dirigible Hindenburg in 1937, Congress regulated the sale of helium, and its availability was further reduced during World War II. After the war, with the advent of pharmacologic bronchodilators with improving side-effect profiles, helium was cast aside as a treatment for asthma. It was relegated back to filling balloons at parties, where its effect on the voice, making one sound like "Donald Duck," was its main notoriety. There were a few reports of its respiratory usage showing the lack of significant improvement in asthmatic patients[4] and in patients with emphysema.[5] Helium-oxygen was shown to be an effective treatment of upper airway obstruction in 1976,[6] and there were scattered reports for this usage until 1986.[7,8,9]

In 1987, the use of helium-oxygen in the treatment of patients with asthma resurfaced in Hartford, CT, and in France, and it became known as heliox. Within a few years, its use spread to Camden, NJ, Chicago, IL, Houston, TX and then to many other sites. Despite anecdotal reports of its efficacy,[10,11,12,13,14] heliox therapy for asthma patients continued to be viewed as experimental because of the lack of randomized controlled trials.[15,16]

The theoretical basis behind the use of helium in asthma patients mainly relates to its low density. It has the lowest density of any gas except hydrogen. Asthma is a disorder of airways obstruction, and the pathophysiology includes an increased turbulent flow in the airways. Since airway resistance in turbulent flow is directly related to the density of a gas, helium with its lower density results in a lower airway resistance. It also reduces the Reynolds number, converting turbulent flow to laminar flow and further decreasing airway resistance. These effects result in a decreased work of breathing. Helium also increases the diffusion of carbon dioxide and may improve alveolar ventilation, resulting in improved gas exchange. Helium is an inert element and does not interact with any biochemical process. It is noncombustible, nonexplosive, and nondetectable by taste and smell. Its effect on the airways occurs and goes away within a few breaths. In summary, it is an extremely safe and rapid-acting therapeutic agent that reduces airway resistance, decreases the work of breathing, and may improve gas exchange.

So what is its downside? The cost for heliox is in the range of $30 to $70 for 8 h of usage, making it a rather low-cost medical modality.[17] However, its usage takes a little knowledge and work. Heliox needs to be dispensed via a nonrebreathing mask, so it is not diluted with room air. The heliox tanks have to be obtained and, despite their large size, have to be easily accessible to the emergency department and/or ICU. Educational sessions have to be set up with respiratory therapists and with the staffs of the emergency department and ICU. There are few guidelines in the medical literature on optimal patient selection and usage.

In cases in which it has been beneficial, the rapidity and power of the therapeutic effect can be truly amazing. Two cases that I was involved with come to mind. In 1987, a young asthmatic patient went into respiratory failure and, despite all known treatments including halothane general anesthesia, was unable to be adequately ventilated. With heliox, the peak airway pressure and the Paco2 markedly dropped in only a few minutes. Another young asthmatic patient, who had a pH of 6.95, refused endotracheal intubation. As with the prior patient, only a few minutes after initiating heliox, the patient had dramatic relief of dyspnea and the Paco2 mark-edly diminished toward the normal range. However, not all asthmatic patients have such profound response to heliox. This anecdotal use of heliox in asthma patients led to three clinical studies[11,12,13] at Hartford and Mount Sinai hospitals (Hartford, CT), which were published between 1989 and 1995. These studies, in patients with acute ventilatory failure who were and were not receiving mechanical ventilation, demonstrated a dramatic decrease in Paco2 in a great majority of patients, but not all. Heliox was still not accepted as a therapeutic choice for the treatment of acute severe asthma and was relegated to a grab bag of unconventional treatments due to the lack of a randomized controlled study demonstrating its efficacy.15,16 However, this interest in heliox spawned other clinical trials across the country in patients with stridor,18,19 bronchiolitis,[20] croup,[21] and COPD,22,23 as well as investigations of its effect on nebulizer and ventilator function.[24,25,26,27,28]

In the article in this issue of CHEST (see page 882), Ho et al reviewed eight randomized controlled trials[29,30,31,32,33,34,35,36] of heliox in acute severe asthma published between 1996 and 2002. Five of these studies used peak expiratory flow rate (PEFR) as the main variable.[29,30,31,32,33] Two trials studied only children,29,30 two trials studied only adults,31,32 and one trial included both children and adults.[33] One trial[30] with children was excluded because it did not include percent predicted PEFR values. The data from the remaining four studies were pooled and evaluated with a meta-analysis. The authors found a small benefit in PEFR and dyspnea index with heliox and commented that the difference may have been even greater if the fifth study had been included. They also suggested that patients with more severe asthma might benefit more from heliox.

Markedly successful anecdotal reports of heliox treatment in asthma patients have been both a blessing and a curse for heliox. They have led to a wider but indiscriminate usage of heliox. In both of the hospitals where I have conducted clinical trials with heliox in asthma patients, its use in treating a small number of patients who had rapid and marked improvement with heliox has led to its regular use in patients with severe asthma. In reviewing the medical literature on heliox in asthma, Ho et al found that of the 13 randomized and nonrandomized clinical trials, 10 showed a benefit with heliox and 3 did not. However, even after the publication of randomized controlled trials of heliox in asthmatic patients, there was no widespread acceptance of heliox therapy. Despite the fact that heliox does not lead to improvement in every patient, it still has clinical value when used with the appropriate patients.

So who should receive heliox? Presently, it should be reserved for the "brittle" asthmatic patient who does not quickly respond to inhaled ß-agonist therapy and who has any of the following characteristics:

  1. Severe airflow obstruction (ie, PEFR, < 30% predicted) and a rapid onset of exacerbation of symptoms preferably over < 24 h but no > 72 h;

  2. A history of labile asthma and/or previous tracheal intubation for asthma; and

  3. The inability to be adequately ventilated on mechanical ventilation.

How should heliox be used?

  1. It should be started as soon as possible.

  2. If there is no subjective or objective improvement within a few minutes, alternative therapies should sought out. The main danger of heliox is continuing it too long when there is no benefit.

  3. It should be used for at least 1 h but usually is not needed beyond 8 h. Every hour or two, the heliox can be removed and the patient can be assessed for deterioration over a few minutes.

  4. The more severe the patient's condition is, the higher the percentage of helium should be, with a maximum of 80% and a minimum of 60%.

As stated by Ho et al, further studies are needed, specifically to ascertain whether heliox reduces the incidence of endotracheal intubation. Since it is but a therapeutic bridge until the effect of corticosteroids occurs, it is unlikely that it will reduce hospital admissions, hospital or ICU length of stay, or hospital mortality. It will provide rapid and marked relief of dyspnea to many patients without any detrimental effects. Since its therapeutic index is so high and its onset and offset of action are so rapid, it may find a useful niche in the prehospital setting when used by emergency medical technicians and possibly by an occasional labile asthmatic patient at home.

Jonathan E. Kass, MD, FCCP, Camden, NJ

Dr. Kass is Associate Professor of Medicine, Division of Pulmonary and Critical Care Medicine, The Cooper Health System, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson School of Medicine at Camden.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (e-mail: permissions@chestnet.org).

Correspondence to: Jonathan E. Kass, MD, FCCP, Division of Pulmonary and Critical Care Medicine, Three Cooper Plaza, Suite 312, Camden, NJ 08103; E-mail: kass-jonathan@cooperhealth.edu.

  1. Barach AL. Use of helium as a new therapeutic gas. Proc Soc Exp Biol Med 1934; 32:462-464

  2. Barach AL. Rare gases not essential to life. Science 1934; 80:593

  3. Barach AL. The use of helium in the treatment of asthma and obstructive lesions of the larynx and trachea. Ann Intern Med 1935; 9:739-765

  4. Schiller IW, Lowell FC, Lynch MY, et al. The effect of helium oxygen mixtures on pulmonary function in asthmatic patients. J Allergy 1955:11-14

  5. Grape B, Channin E, Tyler JM. The effect of helium and oxygen mixtures on pulmonary resistance in emphysema. Am Rev Respir Dis 1960; 81:823-829

  6. Lu TS, Ohmura A, Wong KC et al. Helium-oxygen in the treatment of upper airway obstruction. Anesthesiology 1976; 45:678-680

  7. Skrinskas GJ, Hyland RH, Hutcheon MA. Using helium-oxygen mixtures in the management of acute upper airway obstruction. Can Med Assoc J 1983; 128:555-558

  8. TenEyck LG, Colgan FJ. Methods and guidelines for mechanical ventilation with helium-oxygen for severe upper-airway obstruction. Respir Care 1984; 29:155-159

  9. Curtis JL, Mahlmeister M, Stulberg MS, et al. Helium-oxygen gas therapy: use and availability for the emergency treatment of the inoperable airway obstruction. Chest 1986; 90:455-457

  10. Martin-Barbaz F, Barnoud D, Carpenter F, et al. The use of helium and oxygen mixtures in status asthmaticus. Rev Pneumol Clin 1987; 43:186-189

  11. Shiue S-T, Gluck EH. The use of helium-oxygen mixtures in the support of patients with status asthmaticus and respiratory acidosis. J Asthma 1989; 26:177-180

  12. Gluck EH, Onorato DJ, Castriotta R. Helium-oxygen mixtures in intubated patients with status asthmaticus and respiratory acidosis. Chest 1990; 98:693-698

  13. Kass JE, Castriotta RJ. Heliox therapy in acute severe asthma. Chest 1995; 107:757-760

  14. Manthous CA, Hall JB, Melmed A, et al. Heliox improves pulsus paradoxus and peak expiratory flow in nonintubated patients with severe asthma. Am J Respir Crit Care Med 1995; 151:310-314

  15. Madison JM, Irwin RS. Heliox for asthma: a trial balloon. Chest 1995; 107:597-598

  16. Corbridge TC, Hall JB. The assessment and management of adults with status asthmaticus. Am J Respir Crit Care Med 1995; 151:1296-1316

  17. Manthous CA, Morgan SM, Hall JB, et al. Heliox in the treatment of airflow obstruction: a critical review of the literature. Respir Care 1997; 42:1034-1042

  18. Kemper KJ, Ritz RH, Benson MS, et al. Helium-oxygen mixture in the treatment of postextubation stridor in pediatric trauma patients. Crit Care Med 1991; 19:356-359

  19. Rodelberg DA, Easter AJ, Washam MA, et al. Use of a helium-oxygen mixture in the treatment of postextubation stridor in pediatric patients with burns. J Burn Care Rehabil 1995; 16:476-480

  20. Hollman G, Shen G, Strauss R, et al. Helium-oxygen improves clinical asthma scores in children with acute bronchi-olitis. Crit Care Med 1998; 26:1731-1736

  21. Terregino CA, Nairn SA, Kass JE, et al. The effect of heliox on croup: a pilot study. Acad Emerg Med 1998; 5:1130-1133

  22. Jolliet P, Tassaux D, Chevrolet J-C, et al. Beneficial effects of helium:oxygen versus air:oxygen noninvasive pressure support in patients with decompensated chronic obstructive pulmonary disease. Crit Care Med 1999; 27:2422-2429

  23. Jaber S, Fodiol R, Brochard L, et al. Noninvasive ventilation with helium-oxygen in acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:1191-1200

  24. Anderson M, Svartengren M, Bylin G, et al. Deposition in asthmatics of particles inhaled in air or in helium-oxygen. Am Rev Respir Dis 1993; 147:524-528

  25. Hess DR, Acosta FL, Camargo CA, et al. The effect of heliox on nebulizer function using a ß-agonist bronchodilator. Chest 1999; 115:184-189

  26. Goode ML, Fink JB, Tobin MJ, et al. Improvement in aerosol delivery with helium-oxygen mixtures during mechanical ventilation. Am J Respir Crit Care Med 2001; 163:109-114

  27. Tassaux D, Jolliet P, Chevrolet J-C, et al. Calibration of seven ICU ventilators for mechanical ventilation with helium-oxygen mixtures. Am J Respir Crit Care Med 1999; 160:22-32

  28. Oppenheim-Eden A, Cohen Y, Weissman C, et al. The effect of helium on ventilator performance. Chest 2001; 120:528-588

  29. Carter ER, Webb CRT, Moffit DR. Evaluation of heliox in children hospitalized with acute severe asthma. Chest 1996; 109:1256-1261

  30. Kudukis TM, Manthous CA, Schmidt GA, et al. Inhaled helium- oxygen revisited: effect of inhaled helium-oxygen during the treatment of status asthmaticus in children. J Pediatr 1997; 130:217-224

  31. Kass JE, Terregino CA. The effect of heliox in acute severe asthma: a randomized controlled trial. Chest 1999; 116:296-300

  32. Henderson SO, Acharya P, Kilaghbian T, et al. Use of heliox-driven nebulizer therapy in the treatment of acute asthma. Ann Emerg Med 1999; 33:141-146

  33. Dorfman TA, Shipley ER, Burton JH, et al. Inhaled heliox does not benefit ED patients with moderate to severe asthma [letter]. Am J Emerg Med 2000; 18:495-497

  34. L'Her E, Monchi M, Joly B, et al. Helium-oxygen breathing in the early emergency care of acute severe asthma: a randomized pilot study. Eur J Emerg Med 2000; 7:271-275

  35. Kress JP, Noth I, Hall JB, et al. The utility of albuterol nebulized with heliox during acute asthma exacerbations. Am J Respir Crit Care Med 2002; 165:1317-1321

  36. Rose JS, Panacek EA, Miller P. Prospective randomized trial of heliox-driven continuous nebulizers in the treatment of asthma in the emergency department. J Emerg Med 2002; 22:133-137

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....